Chimeric antigen receptor T-cell therapy.
Chimeric antigen receptor T-cell therapy. Provides that a policy of accident and sickness insurance or health maintenance organization contract that provides coverage for chimeric antigen receptor (CAR) T-cell therapy may not refuse to contract or deny coverage for the administration of any CAR T-cell therapy by any provider that qualifies as a certified health care facility by the federal Food and Drug Administration for the applicable CAR T-cell therapy.
← Back to Jean Leising's profile
{# E23 (Nick, ruling section 1 answer 10): quoting a bill or a court opinion works
the way quoting a news article works. Select a passage above and the same panel
opens: the passage goes to the official you choose, with this document's own
address as its source and its own type. #}